Compare FCEL & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCEL | QURE |
|---|---|---|
| Founded | 1969 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 3.2B |
| IPO Year | 2005 | 2013 |
| Metric | FCEL | QURE |
|---|---|---|
| Price | $22.03 | $47.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $8.31 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 8.3M | 1.4M |
| Earning Date | 06-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.24 | ★ 29.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $89,437,000.00 | $13,107,000.00 |
| Revenue This Year | $4.77 | $126.12 |
| Revenue Next Year | $42.46 | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.78 | $8.73 |
| 52 Week High | $37.88 | $71.50 |
| Indicator | FCEL | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 62.63 |
| Support Level | $17.33 | $20.73 |
| Resistance Level | $26.16 | $50.47 |
| Average True Range (ATR) | 2.54 | 2.26 |
| MACD | 0.12 | 0.33 |
| Stochastic Oscillator | 47.61 | 86.07 |
FuelCell Energy Inc is a clean energy technology company engaged in the development, design, production, and servicing of high temperature fuel cells for clean electric power generation. The Company provides proprietary molten carbonate fuel cell systems that generate electricity electrochemically with ultra low emissions and high efficiency, and operates as a solutions provider managing the design, manufacturing, installation, and maintenance of its systems under long term power purchase, service, and engineering procurement agreements. The Company serves utilities, data centers, and commercial and industrial customers, and operates in the United States, South Korea, Europe, and Canada, with maximum revenue generated from the United States.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.